Browse our 650+ Publications
Latest Publications
A simple assay to quantify mycobacterial lipid antigen-specific T cell receptors in human tissues and blood
Zhou AX, et al.
January 2022
Authors and Affiliates
Angela X Zhou 1,2, Thomas J Scriba 3, Cheryl L Day 4, Deanna A Hagge 5, Chetan Seshadri 1,2;
1 Department of Medicine, University of Washington, Seattle, Washington, United States of America.
2 Tuberculosis Research and Training Center, University of Washington, Seattle, Washington, United States of America.
3 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
4 Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
5 Mycobacterial Research Laboratories, Anandaban Hospital, Kathmandu, Nepal.
Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report
Aran A, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
Andrea Aran 1, Vicente Peg 2, Rosa Maria Rabanal 3, Cristina Bernadó 4, Esther Zamora 5, Elisa Molina 1, Yago A Arribas 1, Joaquín Arribas 4,6,7,8, José Pérez 9, Carme Roura-Mir 1, Montserrat Carrascal 10, Javier Cortés 5 9, Mercè Martí 1;
1 Immunology Unit, Department of Cell Biology, Physiology and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
2 Translational Molecular Pathology, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
3 Unitat de Patologia Murina i Comparada, Department of Animal Medicine and Surgery, Veterinary Faculty, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
4 Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
5 Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
6 Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
7 Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
8 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
9 International Breast Cancer Center (BCC), Quironsalud Group, Barcelona, Spain.
10 Biological and Environmental Proteomics, Institute of Biomedical Research of Barcelona, Spanish National Research Council, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IIBB-CSIC/IDIBAPS), Barcelona, Spain.
Impact of T Cell Repertoire Diversity on Mortality Following Cord Blood Transplantation
Milano F, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
F Milano 1,2, R O Emerson 3, R Salit 1,2, K A Guthrie 1, L A Thur 1, A Dahlberg 1,4, H S Robins 1,3, C Delaney 1,4;
1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
2 Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States.
3 Adaptive Biotechnologies, Seattle, WA, United States.
4 Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Forde PM, et al.
Nature Medicine
January 2022
Authors and Affiliates
Patrick M. Forde 1,2,14, Valsamo Anagnostou 1,2,14, Zhuoxin Sun 3,4,14, Suzanne E. Dahlberg 5, Hedy L. Kindler 6, Noushin Niknafs 1, Thomas Purcell 7, Rafael Santana-Davila 7, Arkadiusz Z. Dudek 8, Hossein Borghaei 9, Mara Lanis 1, Zineb Belcaid 1, Kellie N. Smith 1,2, Archana Balan 1, James R. White 1, Christopher Cherry 1, I. K. Ashok Sivakumar 10, Xiaoshan M. Shao 10,11, Hok Yee Chan 1,2, Dipika Singh 1,2, Sampriti Thapa 1,2, Peter B. Illei 1,12, Drew M. Pardoll 1,2, Rachel Karchin 1,10,11, Victor E. Velculescu 1,2,11,12, Julie R. Brahmer 1,2 and Suresh S. Ramalingam 13;
1 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pforde1@jhmi.edu.
2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pforde1@jhmi.edu.
3 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu.
4 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu.
5 ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
6 Frontier Science Foundation, Boston, MA, USA.
7 Boston Children's Hospital, Boston, MA, USA.
8 University of Chicago Medicine, Chicago, IL, USA.
9 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
10 University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
11 Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA.
12 Fox Chase Cancer Center, Philadelphia, PA, USA.
13 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
14 Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA.
15 Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
16 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
17 Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA.
# Contributed equally.
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
Pulsipher MA, et al.
Blood Cancer Discovery
January 2022
Authors and Affiliates
Michael A. Pulsipher1, Xia Han2, Shannon L. Maude3,4, Theodore W. Laetsch3,4,5, Muna Qayed6,7, Susana Rives8, Michael W. Boyer9, Hidefumi Hiramatsu10, Gregory A. Yanik11, Tim Driscoll12, G. Doug Myers13, Peter Bader14, Andre Baruchel15,16, Jochen Buechner17, Heather E. Stefanski18, Creton Kalfoglou2, Kevin Nguyen2, Edward R. Waldron2, Karen Thudium Mueller2, Harald J. Maier19, Gabor Kari19, and Stephan A. Grupp3,4
1Section of Transplantation and Cellular Therapy, Children’s Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California. 2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. 5Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas. 6Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 7Aflac Cancer and Blood Disorders Center, Healthcare of Atlanta, Atlanta, Georgia. 8Pediatric Hematology, Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain. 9Department of Pediatrics and Internal Medicine, University
of Utah, Salt Lake City, Utah. 10Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan. 11Michigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children’s Hospital, Ann Arbor, Michigan. 12Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina. 13Pediatric Hematology and Oncology, Children’s Mercy Hospital; University of Missouri—Kansas City School of Medicine, Kansas City, Missouri. 14Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany. 15Pediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré (APHP), Paris, France. 16Université de Paris et Institut de Recherche SaintLouis (EA3518), Paris, France. 17Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway. 18Department of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota. 19Novartis Pharmaceuticals Corporation, Basel, Switzerland.
Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma.
Olszewski AJ, et al.
Blood Advances
December 2021
Authors and Affiliates
Adam J Olszewski, MD,1,2 Anna D Chorzalska, PhD,3 Max Petersen,3 Thomas A Ollila, MD,1,2 Adam Zayac, MD,1,2 Habibe Kurt, MD,4 Diana O Treaba, MD,4 John L Reagan, MD,1,2 Andrew Hsu, MD,1,2 Pamela C Egan, MD,1,2 James Butera, MD,1,2 Rabin Niroula, MBBS,1,2 John Vatkevich,5Jordan Robison, CRA,5Ilyas Sahin, MD,1,2 Allison P Jacob, MS,6 Chelsea D Mullins, BS,6and Patrycja M Dubielecka, PhD 2,3
1 Department of Medicine, Alpert Medical School of Brown University, Providence, RI 2 Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI 3 Signal Transduction Lab, Alpert Medical School of Brown University and Rhode Island
Hospital, Providence, RI 4 Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, RI 5 Lifespan Oncology Clinical Research, Rhode Island Hospital, Providence, RI 6 Adaptive Biotechnologies, Seattle, WA
Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells.
Wong SW, et al.
Frontiers in Oncology
December 2021
Authors and Affiliates
Sandy W. Wong1, Nina Shah1, Guy Ledergor 1, Thomas Martin1, Jeffrey Wolf 1 ,Amy M. Shui 2, Chiung-Yu Huang2 and Joaquin Martinez-Lopez 1,3
1 Bone Marrow Transplantation and Hematologic Malignancy Unit, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, United States, 2 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States, 3 Hospital Universitario 12 de Octubre, Complutense University, Centro Nacional de investigacion en Oncolgia (CNIO), i+12, CIBER de oncologia (CIBERONC), Madrid, Spain
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD, et al.
Lancet Haematology
December 2021
Authors and Affiliates
Jacob D Soumerai, Anthony R Mato, Ahmet Dogan, Venkatraman E Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim Hochberg, Jeffrey A Barnes, Audrey M Hamilton, Jeremy S Abramson, Connie L Batlevi, Matthew J Matasar, Ariela Noy, Colette N Owens, M Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Lauren Ramos, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista Scorsune, Julia Lynch, Brianne McGree, Stephanie Hughes, Clare Grieve, Lindsey E Roeker, Meghan Thompson, P Connor Johnson, Mikhail Roshal, Jane Huang, Juliana Biondo, Qun Wu, Allison Jacob, Omar Abdel-Wahab, and Andrew D Zelenetz
Massachusetts General Hospital Cancer Center, Boston, MA, USA (J D Soumerai MD, E Hochberg MD, J A Barnes MD, J S Abramson MD, T Takvorian MD, L Ramos BS, N Nolet MHA, P C Johnson MD, E Simkins MPH, J Ruiters BS, S Sechio BS, D Portman BS, R Martignetti RN, K Scorsune NP, J Lynch NP, B McGree NP); Memorial-Sloan Kettering Cancer Center, New York, NY, USA (A R Mato MD, Prof A Dogan MD, V E Seshan PhD, E Joffe MD, K Flaherty BS, J Carter PA, A M Hamilton MD, C L Batlevi MD, M J Matasar MD, Prof A Noy MD, C N Owens MD, M L Palomba MD, A Kumar MD, A Ni PhD, M Choma BS, C Friedman BA, P Chadha MPH, N Mahajan NP, J Mi NP, S Hughes BS, C Grieve BA, L E Roeker MD, M Thompson MD, M Roshal MD, Prof O Abdel-Wahab MD, Prof A D Zelenetz MD); Beigene, San Mateo, CA, USA (J Huang MD); Genentech, San Francisco, CA, USA (J Biondo MD, Q Wu PhD); Adaptive Biotechnologies, Seattle, WA, USA (A Jacob MS)
Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P, et al.
Clinical Chemistry
November 2021
Authors and Affiliates
Pieter Langerhorst,a, Somayya Noori ,b, Marina Zajec,b,c Yolanda B. De Rijke,c Jolein Gloerich,a Alain J. van Gool,a He´le`ne Caillon,d Irma Joosten,a Theo M. Luider,b Jill Corre,e Martijn M. VanDuijn,b, Thomas Dejoie,d, and Joannes F.M. Jacobsa
aDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; bDepartment of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands; cDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands; dLaboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France; eUnite de Genomique du Myelome, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.